secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001493152-25-008306
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma corporate update: Phase 2 glioblastoma trial 40% enrolled; no financial results
--------------------------------------------------------------------------------

- Phase 2 trial of Ropidoxuridine for glioblastoma: 17 of 40 initial patients enrolled (40%), 8 completed all 7 cycles.
- Trial conducted at Georgetown, Allegheny Health Network, UNC, UVA, Hackensack, Miami Cancer Institute.
- Diagnostics subsidiary entered sponsored research agreement with UCSF to develop PSMA ligand as theranostic.
- CEO Dr. Anatoly Dritschilo invested $237,500 along with other investors in recent financing.
- Launched new corporate website highlighting dual approach to cancer therapeutics and diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225008306/0001493152-25-008306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225008306/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer